These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1244 related items for PubMed ID: 22417847

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P, Levidou G, Trigka EA, Prekete N, Karlou M, Thymara I, Sakellariou S, Fragkou P, Isaiadis D, Pavlopoulos P, Patsouris E, Saetta AA.
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.
    López-Knowles E, Hernández S, Malats N, Kogevinas M, Lloreta J, Carrato A, Tardón A, Serra C, Real FX.
    Cancer Res; 2006 Aug 01; 66(15):7401-4. PubMed ID: 16885334
    [Abstract] [Full Text] [Related]

  • 6. FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.
    Jebar AH, Hurst CD, Tomlinson DC, Johnston C, Taylor CF, Knowles MA.
    Oncogene; 2005 Aug 04; 24(33):5218-25. PubMed ID: 15897885
    [Abstract] [Full Text] [Related]

  • 7. PIK3CA gene alterations in bladder cancer are frequent and associate with reduced recurrence in non-muscle invasive tumors.
    Dueñas M, Martínez-Fernández M, García-Escudero R, Villacampa F, Marqués M, Saiz-Ladera C, Duarte J, Martínez V, Gómez MJ, Martín ML, Fernández M, Castellano D, Real FX, Rodriguez-Peralto JL, De La Rosa F, Paramio JM.
    Mol Carcinog; 2015 Jul 04; 54(7):566-76. PubMed ID: 24347284
    [Abstract] [Full Text] [Related]

  • 8. Oncogene alterations in endometrial carcinosarcomas.
    Biscuola M, Van de Vijver K, Castilla MÁ, Romero-Pérez L, López-García MÁ, Díaz-Martín J, Matias-Guiu X, Oliva E, Palacios Calvo J.
    Hum Pathol; 2013 May 04; 44(5):852-9. PubMed ID: 23199529
    [Abstract] [Full Text] [Related]

  • 9. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
    Hernández S, López-Knowles E, Lloreta J, Kogevinas M, Jaramillo R, Amorós A, Tardón A, García-Closas R, Serra C, Carrato A, Malats N, Real FX.
    Clin Cancer Res; 2005 Aug 01; 11(15):5444-50. PubMed ID: 16061860
    [Abstract] [Full Text] [Related]

  • 10. High-resolution melting analysis as a sensitive prescreening diagnostic tool to detect KRAS , BRAF , PIK3CA , and AKT1 mutations in formalin-fixed, paraffin-embedded tissues.
    Ney JT, Froehner S, Roesler A, Buettner R, Merkelbach-Bruse S.
    Arch Pathol Lab Med; 2012 Sep 01; 136(9):983-92. PubMed ID: 22938585
    [Abstract] [Full Text] [Related]

  • 11. Mutational screening of RET, HRAS, KRAS, NRAS, BRAF, AKT1, and CTNNB1 in medullary thyroid carcinoma.
    Schulten HJ, Al-Maghrabi J, Al-Ghamdi K, Salama S, Al-Muhayawi S, Chaudhary A, Hamour O, Abuzenadah A, Gari M, Al-Qahtani M.
    Anticancer Res; 2011 Dec 01; 31(12):4179-83. PubMed ID: 22199277
    [Abstract] [Full Text] [Related]

  • 12. PI3K/AKT pathway activation in bladder carcinogenesis.
    Calderaro J, Rebouissou S, de Koning L, Masmoudi A, Hérault A, Dubois T, Maille P, Soyeux P, Sibony M, de la Taille A, Vordos D, Lebret T, Radvanyi F, Allory Y.
    Int J Cancer; 2014 Apr 15; 134(8):1776-84. PubMed ID: 24122582
    [Abstract] [Full Text] [Related]

  • 13. Activation of the PI3K/AKT signalling pathway in non-melanoma skin cancer is not mediated by oncogenic PIK3CA and AKT1 hotspot mutations.
    Hafner C, Landthaler M, Vogt T.
    Exp Dermatol; 2010 Aug 15; 19(8):e222-7. PubMed ID: 20557351
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. PI3K signaling pathway is activated by PIK3CA mRNA overexpression and copy gain in prostate tumors, but PIK3CA, BRAF, KRAS and AKT1 mutations are infrequent events.
    Agell L, Hernández S, Salido M, de Muga S, Juanpere N, Arumí-Uria M, Menendez S, Lorenzo M, Lorente JA, Serrano S, Lloreta J.
    Mod Pathol; 2011 Mar 15; 24(3):443-52. PubMed ID: 21113138
    [Abstract] [Full Text] [Related]

  • 16. FGFR3, HRAS, KRAS, NRAS and PIK3CA mutations in bladder cancer and their potential as biomarkers for surveillance and therapy.
    Kompier LC, Lurkin I, van der Aa MN, van Rhijn BW, van der Kwast TH, Zwarthoff EC.
    PLoS One; 2010 Nov 03; 5(11):e13821. PubMed ID: 21072204
    [Abstract] [Full Text] [Related]

  • 17. Exploration of genetic alterations in human endometrial cancer and melanoma: distinct tumorigenic pathways that share a frequent abnormal PI3K/AKT cascade.
    Ogawa K, Sun C, Horii A.
    Oncol Rep; 2005 Dec 03; 14(6):1481-5. PubMed ID: 16273242
    [Abstract] [Full Text] [Related]

  • 18. Presence of somatic mutations within PIK3CA, AKT, RAS, and FGFR3 but not BRAF in cisplatin-resistant germ cell tumors.
    Feldman DR, Iyer G, Van Alstine L, Patil S, Al-Ahmadie H, Reuter VE, Bosl GJ, Chaganti RS, Solit DB.
    Clin Cancer Res; 2014 Jul 15; 20(14):3712-20. PubMed ID: 24812411
    [Abstract] [Full Text] [Related]

  • 19. Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.
    Zieger K, Dyrskjøt L, Wiuf C, Jensen JL, Andersen CL, Jensen KM, Ørntoft TF.
    Clin Cancer Res; 2005 Nov 01; 11(21):7709-19. PubMed ID: 16278391
    [Abstract] [Full Text] [Related]

  • 20. Analysis of PIK3CA Mutations and Activation Pathways in Triple Negative Breast Cancer.
    Cossu-Rocca P, Orrù S, Muroni MR, Sanges F, Sotgiu G, Ena S, Pira G, Murgia L, Manca A, Uras MG, Sarobba MG, Urru S, De Miglio MR.
    PLoS One; 2015 Nov 01; 10(11):e0141763. PubMed ID: 26540293
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 63.